MDS Pharma Investigating Bioequivalence Test Failures
Executive Summary
MDS Pharma is testing hypotheses to determine the root cause of bioequivalence test failures experienced at the company's Montreal bioanalytical facility over the last five years
You may also be interested in...
MDS Pharma cited in FDA manufacturing letter
FDA will scrutinize MDS Pharma Services' bioequivalence studies on a case-by-case basis because the company's approach to investigating contamination sources in such studies is inadequate, the agency says in an April 26 "untitled" 1letter. The enhanced scrutiny could result in "additional inspections, third-party audits, and rejection of data," the letter says. The letter follows two failed inspections...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials